1887

Chapter 14 : Cell Lines: Applications and Biosafety

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Cell Lines: Applications and Biosafety, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch14-1.gif /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch14-2.gif

Abstract:

Animal cells have been used in biotechnology since the early 1950s. The Salk polio vaccine, licensed in 1954, was the first product produced on animal cells as a substrate, and for many years the only products produced using animal cells were viral vaccines. Primary animal cells were used for many years for vaccine production and are still used in certain cases. These vaccines have generally proven to be acceptable and safe, but there are notable exceptions that have directed manufacturers and regulatory bodies to be very cautious in their assessment of new cell substrates. The earliest cell lines used to manufacture biological products were human diploid fibroblast finite cell lines. WI-38 and MRC-5, two of the best-known examples, have been used in the manufacture of a number of licensed products (Table 1). The early use of continuous cell lines (CCLs) for the manufacture of biological products is represented by the manufacture of foot-and-mouth disease vaccine in the Syrian hamster cell line BHK, the production of interferon from the B-lymphoblastoid cell line Namalwa, and the introduction of monoclonal antibodies from hybridoma cells in the 1990s (for a general reference, see reference 1).

Citation: Stacey G, Hawkins J. 2017. Cell Lines: Applications and Biosafety, p 299-325. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch14
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819637.ch14
1. Griffiths JB,. 2007. The development of animal cell products: history and overview, p 114. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
2. Cooney CL. 1995. Are we prepared for animal cell technology in the 21st century? Cytotechnology 18:38.[PubMed]
3. Lysaght MJ, Jaklenec A, Deweerd E. 2008. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics. Tissue Eng Part A 14:305315.[PubMed]
4. Nerem R.M. 2010. Regenerative medicine: the emergence of an industry. J R Soc Interface 7(Suppl 6):S771S775.
5. Jaklenec A, Stamp A, Deweerd E, Sherwin A, Langer R. 2012. Progress in the tissue engineering and stem cell industry: “Are we there yet?”. Tissue Eng Part B Rev 18:155166.[PubMed]
6. Maziarz RT, Driscoll D. 2011. Hematopoietic stem cell transplantation and implications for cell therapy reimbursement. Cell Stem Cell 8:609612.[PubMed]
7. Abou-El-Enein M, Elsanhoury A, Reinke P. 2016. overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell 19:293297.[PubMed]
8. Petricciani JC. 1995. The acceptability of continuous cell lines: a personal & historical perspective. Cytotechnology 18:913.[PubMed]
9. International Association of Microbiological Societies. 1963. Proceedings: Symposium on the Uses of Human Diploid Cell Strains. Blasnikova-Tiskarna, Lubliana, Zagreb, Croatia.
10. WHO Expert Committee on Biological Standardization and Executive Board. 1998. Requirements for the Use of Animal Cells as In vitro Substrates for the Production of Biologicals. WHO Technical Report Series no. 878. World Health Organization, Geneva, Switzerland.
11. Knezevic I, Stacey G, Petricciani J, Sheets R WHO Study Group on Cell Substrates. 2010. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22–23 April 2009, Bethesda, MD. Biologicals 38:162169.
12. WHO Cell Substrate Study Group. 2010. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Proposed replacement of TRS 878, Annex 1. http://www.who.int/biologicals/BS2132_CS_Recommendations_CLEAN_19_July_2010.pdf.
13. Doroshenko A, Halperin SA. 2009. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 8:679688.
14. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M,, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27:18891897.
15. Genzel Y, Reichl U. 2009. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 8:16811692.
16. Kuczewski M, Schirmer E, Lain B, Zarbis-Papastoitsis G. 2011. A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnol J 6:5665[PubMed]
17. Ross D, Brown T, Harper R, Pamarthi M, Nixon J, Bromirski J, Li CM, Ghali R, Xie H, Medvedeff G, Li H, Scuderi P, Arora V, Hunt J, Barnett T. 2012. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J Biotechnol 162:262273.
18. Sakhuja K, Reddy PS, Ganesh S, Cantaniag F, Pattison S, Limbach P, Kayda DB, Kadan MJ, Kaleko M, Connelly S. 2003. Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 14:243254.
19. European Medicines Agency. 2011. Reflection paper on design modifications of gene therapy medicinal products during development. EMA/CAT/GTWP/44236/2009 (14 December 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500122743.pdf.
20. Damle B, White R, Wang HF. 2015. Considerations for clinical pharmacology studies for biologics in emerging markets. J Clin Pharmacol 55(Suppl 3):S116S122.
21. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299308.[PubMed]
22. Leen AM, Rooney CM, Foster AE. 2007. Improving T cell therapy for cancer. Annu Rev Immunol 25:243265.[PubMed]
23. Kershaw MH, Westwood JA, Darcy PK. 2013. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525541.[PubMed]
24. Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, Exley MA, Stauss H, Maher J, Pule M, Sewell AK, Bendle G, Lee S, Qasim W, Thrasher A, Morris E. 2015. Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Hum Gene Ther 26:276285.[PubMed]
25. Jackson HJ, Rafiq S, Brentjens RJ. 2016. Driving CAR T-cells forward. Nature Rev Clin Oncol 13:370383.
26. Miller AD. 1990. Retrovirus packaging cells. Hum Gene Ther 1:514.[PubMed]
27. Stacey GN, Merten O-W,. 2010. Host cells and cell banking, p 4588. In Al-Rubeai M, Merten O-W (ed), Viral Vectors for Gene Therapy: Methods and Protocols. (Methods in Molecular Biology 1:737). Springer Science+Business Media LLC, New York, NY.
28. Epstein S U.S. Food and Drug Administration. 1996. Addendum to the points to consider in human somatic cell and gene therapy (1991). Hum Gene Ther 7:11811190.[PubMed]
29. U.S. Food and Drug Administration. 2011. Guidance for Industry Potency Tests for Cellular and Gene Therapy Products. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD.
30. European Medicines Agency. 2009. Committee for Medicinal Products for Human Use (CHMP), Doc.EMA/CHMP/GTWP/212377/2008. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500059111.pdf.
31. European Medicines Agency. 2001. Points to consider on the manufacture and quality control of hum somatic cell therapy medicinal products. CPMP/BMP/41450/98. https://www.old.health.gov.il/download/forms/a39_cimmittee.pdf.
32. Esvelt KM, Wang HH. 2013. Genome-scale engineering for systems and synthetic biology. Mol Syst Biol 9:641.
33. Horvath P, Barrangou R. 2010. CRISPR/Cas, the immune system of bacteria and archaea. Science 327:167170.[PubMed]
34. Isasi R, Kleiderman E, Knoppers BM. 2016. Editing policy to fit the genome? Framing genome editing policy requires setting thresholds of acceptability. Science 351:337339.[PubMed]
35. Li MD, Atkins H, Bubela T. 2014. The global landscape of stem cell clinical trials. Regen Med 9:2739.[PubMed]
36. Green H, Kehinde O, Thomas J. 1979. Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci USA 76:56655668.
37. Navsaria HA, Myers SR, Leigh IM, McKay IA. 1995. Culturing skin in vitro for wound therapy. Trends Biotechnol 13:91100.[PubMed]
38. Wu J, Du Y, Watkins SC, Funderburgh JL, Wagner WR. 2011. The engineering of organized human corneal tissue through the spatial guidance of corneal stromal stem cells. Biomaterials 33:13431352.
39. Ende N, Chen R. 2002. Parkinson's disease mice and human umbilical cord blood. J Med 33:173180.[PubMed]
40. Ende N, Chen R, Reddi AS. 2004. Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochem Biophys Res Commun 321:168171.[PubMed]
41. Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB, Simpson S, Moore J, Morrison P, Esmonde T, Chada N, Craufurd D, Snowdon J, Thompson J, Harper P, Glew R, Harper R NEST-UK Collaboration. 2013. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 84:657665.[PubMed]
42. Rocha V, Wagner JE Jr, Sobocinski KA,, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. 2000. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342:18461854.
43. Garcia J. 2010. Allogeneic unrelated cord blood banking worldwide: an update. Transfus Apheresis Sci 42:257263.[PubMed]
44. Rubinstein P. 2009. Cord blood banking for clinical transplantation. Bone Marrow Transplant 44:635642.[PubMed]
45. Hofmeister CCJ, Zhang J, Knight KL, Le P, Stiff PJ. 2007. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 39:1123.[PubMed]
46. Ge J, Cai H, Tan WS. 2011. Chromosomal stability during ex vivo expansion of UCB CD34(+) cells. Cell Prolif 44:550557.
47. Corselli M, Parodi A, Mogni M, Sessarego N, Kunkl A, Dagna-Bricarelli F, Ibatici A, Pozzi S, Bacigalupo A, Frassoni F, Piaggio G. 2008. Clinical scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor cells is associated with high incidence of karyotype aberrations. Exp Hematol 36:340349.[PubMed]
48. Crow J, Youens K, Michalowski S, Perrine G, Emhart C, Johnson F, Gerling A, Kurtzberg J, Goodman BK, Sebastian S, Rehder CW, Datto MB. 2010. Donor cell leukemia in umbilical cord blood transplant patients. A case study and literature review highlighting the importance of molecular engraftment analysis. J Mol Diagn 12:530537.
49. Kassem M, Kristiansen M, Abdallah BM. 2004. Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 95:209214.[PubMed]
50. Calloni R, Cordero EA, Henriques JA, Bonatto D. 2013. Reviewing and updating the major molecular markers for stem cells. Stem Cells Devel 22:14551476.
51. Nombela-Arrieta C, Ritz J, Silberstein LE. 2011. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 12:126131.[PubMed]
52. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 99:89328937.[PubMed]
53. Ishikane S, Ohnishi S, Yamahara K, Sada M, Harada K, Mishima K, Iwasaki K, Fujiwara M, Kitamura S, Nagaya N, Ikeda T. 2008. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells 26:26252633.[PubMed]
54. Nakajima H, Uchida K, Guerrero AR, Watanabe S, Sugita D, Takeura N, Yoshida A, Long G, Wright KT, Johnson WE, Baba H. 2012. Transplantation of mesenchymal stem cells promotes the alternative pathway of macrophage activation and functional recovery after spinal cord injury. J Neurotrauma 29:16141625.
55. Puglisi MA, Tesori V, Lattanzi W, Piscaglia AC, Gasbarrini GB, D'Ugo DM, Gasbarrini A. 2011. Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol 2011:860578.
56. Biancone L, Bruno S, Deregibus MC, Tetta C, Camussi G. 2012. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 27:30373042.
57. Evans MJ, Kaufman MH. 1981. Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154156.
58. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282:11451147.[PubMed]
59. Taylor CJ, Bolton EM, Bradley JA. 2011. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 366:23122322.
60. Barry J, Hyllner J, Stacey G, Taylor CJ, Turner M. 2015. Setting up a haplobank: issues and solutions. Curr Stem Cell Rep 1:110117.[PubMed]
61. Fairchild PJ. 2010. The challenge of immunogenicity in the quest for induced pluripotency. Nat Rev Immunol 10:868875.
62. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861872.[PubMed]
63. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH. 2011. Somatic coding mutations in human induced pluripotent stem cells. Nature 471:6367.
64. Lund RJ, Närvä E, Lahesmaa R. 2012. Genetic and epigenetic stability of human pluripotent stem cells. Nat Rev Genet 13:732744.[PubMed]
65. Zhao T, Zhang ZN, Rong Z, Xu Y. 2011. Immunogenicity of induced pluripotent stem cells. Nature 474:212215
66. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. 2013. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12:407412.
67. International Stem Cell Initiative. 2011. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 29:11321144.[PubMed]
68. Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden H, Andrews PW. 2007. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat. Biotechnol 25:207221.
69. U.S. Food and Drug Administration. 2007. Guidance for Industry: Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)—Small Entity Compliance Guide. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm073366.htm.
71. EUTCD. 2004. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004: Setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissue and cells. L102/48, Official Journal of the European Union, 7.4.2004.
71. Global Programme for Vaccines and Immunization. 1997. The WHO Guide to Good Manufacturing Practice (cGMP) Requirements. World Health Organization, Geneva, Switzerland.
72. Keirstead HS, Nistor G, Bernal G, Totoiu M, Cloutier F, Sharp K, Steward O. 2005. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 25:46944705.
73. Hayakawa T, Aoi T, Bravery C, Hoogendoorn K, Knezevic I, Koga J, Maeda D, Matsuyama A, McBlane J, Morio T, Petricciani J, Rao M, Ridgway A, Sato S, Sato Y, Stacey G, Trouvin J-H, Umezawa A, Yamato M, Yano K, Yokote H, Yoshimatsu K,, Zorzi-More P. 2015. Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products. Biologicals 43:283297.
74. British Standards Institute Regenerative Medicines Committee. 2011. PAS 93:2011: Characterization of Human Cells for Clinical Applications. Guide. British Standards Institute, London, United Kingdom.
75. Sheridan B, Stacey G, Wilson A, Ginty P, Bravery C, Marshall D. 2012. Standards can help bring products to market. Bioprocess Int 10:1820.
76. Williams DJ, Archer R, Archibald P, Bantounas I, Baptista R, Barker R, Barry J, Bietrix F, Blair N, Braybrook J, Campbell J. 2016. Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015. Regenerative Med 11:483492.
77. U.S. Food and Drug Administration. 1998. Guidance for Industry Guidance for Human Somatic Cell Therapy and Gene Therapy. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm072987.htm.
78. Wobus AM, Löser P. 2011. Present state and future perspectives of using pluripotent stem cells in toxicology research. Arch Toxicol 85:79117.
79. Stacey GN, Coecke S, Price A, Healy L, Jennings P, Wilmes A, Pinset C, Sundstrom M, Myatt G,. 2016. Ensuring the quality of stem cell derived models for toxicity testing, p 259297. In Eskes C, Whelan M (ed), Validation of Alternative Methods for Toxicity Testing. Springer, New York, NY.
80. Pamies D, Bal-Price A, Simeonov A, Tagle D, Allen D, Gerhold D, Yin D, Pistollato F, Inutsuka T, Sullivan K, Stacey G. 2016. Good Cell Culture Practice for stem cells and stem-cell-derived models. ALTEX Online August 23, 2016, version 2. http://dx.doi.org/10.14573/altex.1607121.
81. Frommer W, Archer L, Boon B, Brunius G, Collins CH, Crooy P, Doblhoff-Dier O, Donikian R, Economidis J, Frontali C, Gaal T, Hamp S, Haymerle H, Houwink EH, Küenzi MT, Krämer P, Lelieveld HLM, Logtenberg MT, Lupker J, Lund S, Mahler JL, Mosgaard C, Normand-Plessier F, Rudan F, Simon R, Tuijenburg Muijs G, Vranch SP, Werner RG. 1993. Safe biotechnology (5). Recommendations for safe work with animal and human cell cultures concerning potential human pathogens. Appl Microbiol Biotechnol 39:141147.[PubMed]
82. Jank B, Haymerle H, Doblhoff-Dier O. 1996. Zurich hazard analysis in biotechnology. Nat Biotechnol 14:894896.[PubMed]
83. Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, Lovell-Badge R, Masters JRW, Meredith J, Stacey GN, Thraves P, Vias M Cancer Research UK. 2014. Guidelines for the use of cell lines in biomedical research. Br J Cancer 111:10211046.[PubMed]
84. Roberts PL,. 2007. Virus safety of cell-derived biological products, p 371392. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
85. Andrews PW. , et al. 2015. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med 10(Suppl):144.[PubMed]
86. Davidson WL, Hummeler K. 1960. B virus infection in man. Ann N Y Acad Sci 85:970979.[PubMed]
87. National Research Council. 1989. Prudent Practices for the Handling and Disposal of Infectious Material, p 1333. National Academy Press, Washington, DC.
88. Chesterton N,. 2007. System and process validation, p 285302. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
89. Urnovitz HB, Murphy WH. 1996. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev 9:7299.[PubMed]
90. Patzke S, Lindeskog M, Munthe E, Aasheim HC. 2002. Characterization of a novel human endogenous retrovirus, HERV-H/F, expressed in human leukemia cell lines. Virology 303:164173.
91. Weiss RA. 2001. Adventitious viral genomes in vaccines but not in vaccinees. Emerg Infect Dis 7:153154.
92. Adamson SR. 1998. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Dev Biol Stand 93:8996.[PubMed]
93. Weissmahr RN, Schüpbach J, Böni J. 1997. Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J Virol 71:30053012.[PubMed]
94. Ma H, Khan AS. 2011. Detection of latent retroviruses in vaccine-related cell substrates: investigation of RT activity produced by chemical induction of Vero cells. PDA J Pharm Sci Technol 65:685689.[PubMed]
95. Lloyd G, Jones N. 1986. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J Infect 12:117125.[PubMed]
96. Saïb A, Périès J, de Thé H. 1995. Recent insights into the biology of the human foamy virus. Trends Microbiol 3:173178.[PubMed]
97. Schweizer M, Falcone V, Gänge J, Turek R, Neumann-Haefelin D. 1997. Simian foamy virus isolated from an accidentally infected human individual. J Virol 71:48214824.
98. Huang F, Wang H, Jing S, Zeng W. 2012. Simian foamy virus prevalence in Macaca mulatta and zookeepers. AIDS Res Hum Retrovir 28:591593.
99. Khan AS. 2009. Simian foamy virus infection in humans: prevalence and management. Expert Rev Anti Infect Ther 7:569580.
100. Locatelli S, Peeters M. 2012. Cross-species transmission of simian retroviruses: how and why they could lead to the emergence of new diseases in the human population. AIDS 26:659673.
101. Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, Mulligan D, Butel JS. 2012. Polyomavirus JC urinary shedding in kidney and liver transplant recipients associated with reduced creatinine clearance. J Infect Dis 206:875880.[PubMed]
102. Sood P, Senanayake S, Sujeet K, Medipalli R, Zhu YR, Johnson CP, Hariharan S. 2012. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation 94:814821.[PubMed]
103. van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. 2012. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 70:172183.[PubMed]
104. Löwer J. 1995. Acceptability of continuous cell lines for the production of biologicals. Cytotechnology 18:1520.[PubMed]
105. Lelong-Rebel IH, Piemont Y, Fabre M, Rebel G. 2009. Mycobacterium avium-intracellulare contamination of mammalian cell cultures. In Vitro Cell Dev Biol Anim 45:7590.
106. Kajander EO, Ciftçioglu N. 1998. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc Natl Acad Sci USA 95:82748279.[PubMed]
107. Shiekh FA. 2012. Do calcifying nanoparticles really contain 16S rDNA? Int J Nanomedicine 7:50515052.[PubMed]
108. Kumon H, Matsumoto A, Uehara S, Abarzua F, Araki M, Tsutsui K, Tomochika K. 2011. Detection and isolation of nanobacteria-like particles from urinary stones: long-withheld data. Int J Urol 18:458465.
109. Gray JS, Birmingham JM, Fenton JI. 2009. Got black swimming dots in your cell culture? Identification of Achromobacter as a novel cell culture contaminant. Biologicals 38:273277.
110. Shannon M, Capes-Davis A, Eggington E, Georghiou R, Huschtscha LI, Moy E, Power M, Reddel RR, Arthur JW. 2016. Is cell culture a risky business? Risk analysis based on scientist survey data. Int J Cancer 138:664670.
111. Rottem S, Naot Y. 1998. Subversion and exploitation of host cells by mycoplasmas. Trends Microbiol 6:436440.[PubMed]
112. Uphoff CC, Drexler HG. 2014. Detection of mycoplasma contamination in cell cultures. Curr Protoc Mol Biol 106:114.[PubMed]
113. Uphoff CC, Denkmann SA, Drexler HG. 2012. Treatment of mycoplasma contamination in cell cultures with Plasmocin. J Biomed Biotechnol 2012:267678.
114. Alper T, Cramp WA, Haig DA, Clarke MC. 1967. Does the agent of scrapie replicate without nucleic acid? Nature 214:764766.[PubMed]
115. Griffith JS. 1967. Self-replication and scrapie. Nature 215:10431044.[PubMed]
116. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136144.[PubMed]
117. Aguzzi A, Heikenwalder M. 2006. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 4:765775.
118. Prusiner SB, Collinge J, Powell J, Anderton B (ed). 1992. Prion Diseases of Humans and Animals. Ellis Horwood, London, United Kingdom.
119. Sigurdson CJ, Miller MW. 2003. Other animal prion diseases. Br Med Bull 66:199212.[PubMed]
120. Kovacs GG, Budka H. 2008. Prion diseases: from protein to cell pathology. Am J Pathol 172:555565.[PubMed]
121. European Commission. 2011. European Medicines Agency guidance document. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3). J European Union http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003700.pdf.
122. World Health Organization. 2010. WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies. World Health Organization, Geneva, Switzerland. http://www.who.int/bloodproducts/tse/WHO%20TSE%20Guidelines%20FINAL-22%20JuneupdatedNL.pdf.
123. United Kingdom Department of Health. 2014. Donation of starting material for cell-based advanced therapies: a SaBTO review. U.K. Department of Health. https://www.gov.uk/government/publications/donation-of-starting-material-for-advanced-cell-based-therapies.
124. Gugel EA, Sanders ME. 1986. Needle-stick transmission of human colonic adenocarcinoma. N Engl J Med 315:1487.[PubMed]
125. Centers for Disease Control and Prevention and National Institutes of Health. 1999. Biosafety in Microbiological and Biomedical Laboratories, 4th ed. U.S. Government Printing Office, Washington, DC.
126. Human Medicines Evaluation Unit. 1997. ICH Topic Q 5 D—Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products. European Agency for the Evaluation of Medicinal Products, ICH Technical Co-ordination, London, United Kingdom.
127. Sheng-Fowler L, Cai F, Fu H, Zhu Y, Orrison B, Foseh G, Blair DG, Hughes SH, Coffin JM, Lewis AM Jr, Peden K. 2010. Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc. Int J Biol Sci 6:151162.
128. Garnick RL. 1998. Raw materials as a source of contamination in large-scale cell culture. Dev Biol Stand 93:2129.[PubMed]
129. Erickson GA, Bolin SR, Landgraf JG. 1991. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns. Dev Biol Stand 75:173175.[PubMed]
130. Yanagi M, Bukh J, Emerson SU, Purcell RH. 1996. Contamination of commercially available fetal bovine sera with bovine viral diarrhea virus genomes: implications for the study of hepatitis C virus in cell cultures. J Infect Dis 174:13241327.[PubMed]
131. Xia H, Vijayaraghavan B, Belák S, Liu L. 2011. Detection and identification of the atypical bovine pestiviruses in commercial foetal bovine serum batches. PLoS One 6:e28553.[PubMed]
132. Onyekaba C, Fahrmann J, Bueon L, King P, Goyal SM. 1987. Comparison of five cell lines for the propagation of bovine viral diarrhea and infectious bovine rhinotracheitis viruses. Microbiologica 10:311315.[PubMed]
133. Nakamura S, Shimazaki T, Sakamoto K, Fukusho A, Inoue Y, Ogawa N. 1995. Enhanced replication of orbiviruses in bovine testicle cells infected with bovine viral diarrhoea virus. J Vet Med Sci 57:677681.[PubMed]
134. Nicklas W, Kraft V, Meyer B. 1993. Contamination of transplantable tumors, cell lines, and monoclonal antibodies with rodent viruses. Lab Anim Sci 43:296300.[PubMed]
135. Zhang W, Li L, Deng X, Blümel J, Nübling CM, Hunfeld A, Baylis SA, Delwart E. 2016. Viral nucleic acids in human plasma pools. Transfusion 56:22482255.
136. Jones PA, Wolkowicz MJ, Rideout WM III, Gonzales FA, Marziasz CM, Coetzee GA, Tapscott SJ. 1990. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc Natl Acad Sci USA 87:61176121.[PubMed]
137. Antequera F, Boyes J, Bird A. 1990. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503514.[PubMed]
138. Wilson VL, Jones PA. 1983. DNA methylation decreases in aging but not in immortal cells. Science 220:10551057.[PubMed]
139. Nestor CE, Ottaviano R, Reinhardt D, Cruickshanks HA, Mjoseng HK, McPherson RC, Lentini A, Thomson JP, Dunican DS, Pennings S, Anderton SM, Benson M, Meehan RR. 2015. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol 16:11.[PubMed]
140. Coecke S, Balls M, Bowe G, Davis J, Gstraunthaler G, Hartung T, Hay R, Merten O-W, Price A, Shechtman L, Stacey GN, Stokes W. 2005. Guidance on Good Cell Culture Practice. A report of the second ECVAM Task Force on Good Cell Culture Practice. ATLA 33:127. http://www.atla.org.uk/guidance-on-good-cell-culture-practice
141. Stacey GN,. 2010. Cell culture contamination, p 7791. In Cree IA (ed), Cancer Cell Culture: Methods and Protocols. Springer Science+Business media LLC, New York, NY.
142. Meager A,. 2007. Gene transfer vectors for clinical applications, p 125142. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
143. Kotterman MA, Chalberg TW, Schaffer DV. 2015. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17:6389.[PubMed]
144. Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007—an update. J Gene Med 9:833842.[PubMed]
145. Calvez V, Rixe O, Wang P, Mouawad R, Soubrane C, Ghoumari A, Verola O, Khayat D, Colbère-Garapin F. 1996. Virus-free transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment induces tumor cell death. Clin Cancer Res 2:4751.[PubMed]
146. Lo HW, Day CP, Hung MC. 2005. Cancer-specific gene therapy. Adv Genet 54:235255.[PubMed]
147. OECD Expert Group on Good Laboratory Practice. 1982. Good Laboratory Practice in the Testing of Chemicals. Organisation of Economic Co-operation and Development, Paris, France.
148. OECD. 1998. OECD series on principles of good laboratory practice and compliance monitoring. Number 1. OECD principles on good laboratory practice. ENV/MC/CHEM(98)17. Guideline 33:1172.
149. CBER. 2010. Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. Food and Drug Administration, Bethesda, MD. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/default.htm.
150. Stoll TS,. 2007. Services and associated equipment for upstream processing, p 245285. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
151. Dragunsky E, Chumakov K, Norwood L, Parker M, Lu Z, Ran Y. 1993. Live polio vaccine reversion: impact of cell density. In Vitro 3:123A.
152. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci 848:2839.[PubMed]
153. Committee for Proprietary Medicinal Products Ad Hoc Working Party on Biotechnology/Pharmacy Working Party on Safety Medicines, Committee for Proprietary Medicin. 1991. EEC regulatory document. Note for guidance: validation of virus removal and inactivation procedures. Biologicals 19:247251.[PubMed]
154. Wood DJ, Minor PD. 1990. Meeting report: use of diploid cells in production. Biologicals 18:143146.[PubMed]
155. Nims RW, Shoemaker AP, Bauernschub MA, Rec LJ, Harbell JW. 1998. Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination. In Vitro Cell Dev Biol Anim 34:3539.[PubMed]
156. Hebert PDN, Ratnasingham S, deWaard JR. 2003. Barcoding animal life: cytochrome c oxidase subunit 1 divergences among closely related species. Proc Biol Sci 270(Suppl 1):S96S99.[PubMed]
157. Hebert PDN, Cywinska A, Ball SL, deWaard JR. 2003. Biological identifications through DNA barcodes. Proc Biol Sci 270:313321.[PubMed]
158. Chen TC,. 1998. Identity testing, authentication, karyology, p. 9A:1.19A:1.20. In Doyle A, Griffiths JB,, N ewell DG (ed.), Cell & Tissue Culture: Laboratory Procedures. John Wiley & Sons, Ltd., Chichester, United Kingdom.
159. Vassart G, Georges M, Monsieur R, Brocas H, Lequarre AS, Christophe D. 1987. A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA. Science 235:683684.[PubMed]
160. Jeffreys AJ, Wilson V, Thein SL. 1985. Hypervariable ‘minisatellite’ regions in human DNA. Nature 314:6773.[PubMed]
161. Jeffreys AJ, Wilson V, Thein SL. 1985. Individual-specific ‘fingerprints’ of human DNA. Nature 316:7679.[PubMed]
162. Stacey GN, Bolton BJ, Doyle A. 1991. The quality control of cell banks using DNA fingerprinting. EXS 58:361370.[PubMed]
163. Webb MB, Debenham PG. 1992. Cell line characterisation by DNA fingerprinting; a review. Dev Biol Stand 76:3942.[PubMed]
164. Gilbert DA, Reid YA, Gail MH, Pee D, White C, Hay RJ, O'Brien SJ. 1990. Application of DNA fingerprints for cell-line individualization. Am J Hum Genet 47:499514.[PubMed]
165. Lessa EP, Applebaum G. 1993. Screening techniques for detecting allelic variation in DNA sequences. Mol Ecol 2:119129.[PubMed]
166. Stacey GN, Hoelzl H, Stephenson JR, Doyle A. 1997. Authentication of animal cell cultures by direct visualization of repetitive DNA, aldolase gene PCR and isoenzyme analysis. Biologicals 25:7585.[PubMed]
167. Tarelli E,. 2007. Glycosylation of medicinal products, p 479490. In Stacey G, Davis J (ed), Medicines from Animal Cells. John Wiley & Sons, Chichester, United Kingdom.
168. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. 2012. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 28:147175.[PubMed]
169. International Conference on Harmonisation. 1999. ICH harmonised tripartite guideline: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1) Current Step 4 version dated 23 September. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html
170. Moda F, Gambetti P, Notari S, Concha-Marambio L, Catania M, Park K-W, Maderna E, Suardi S, Haïk S, Brandel J-P, Ironside J, Knight R, Tagliavini F, Soto C. 2014. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med 371:530539.[PubMed]
171. Uryvaev LV, Dedova AV, Dedova LV, Ionova KS, Parasjuk NA, Selivanova TK, Bunkova NI, Gushina EA, Grebennikova TV, Podchernjaeva RJ. 2012. Contamination of cell cultures with bovine viral diarrhea virus (BVDV). Bull Exp Biol Med 153:7781.[PubMed]
172. Vilček S, Herring AJ, Herring JA, Nettleton PF, Lowings JP, Paton DJ. 1994. Pestiviruses isolated from pigs, cattle and sheep can be allocated into at least three genogroups using polymerase chain reaction and restriction endonuclease analysis. Arch Virol 136:309323.[PubMed]
173. Marcus-Sekura C, Richardson JC, Harston RK, Sane N, Sheets RL. 2011. Evaluation of the human host range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the manufacture of biological products. Biologicals 39:359369.[PubMed]
174. Pyra H, Böni J, Schüpbach J. 1994. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc Natl Acad Sci USA 91:15441548.
175. Lovatt A, Black J, Galbraith D, Doherty I, Moran MW, Shepherd AJ, Griffen A, Bailey A, Wilson N, Smith KT. 1999. High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods 82:185200.[PubMed]
176. Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, Delwart EL. 2010. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol 84:60336040.[PubMed]
177. Poiley JA, Bierley ST, Hillesund T, Nelson RE, Monticello TM, Raineri R. 1994. Methods for estimating retroviral burden. Biopharm Manuf 7:3235.
178. Goldsmith CS, Miller SE. 2009. Modern uses of electron microscopy for detection of viruses. Clin Microbiol Rev 22:552563.[PubMed]
179. Hendricks LC, Jordan J, Yang TY, Driesprong P, Haan GJ, Viebahn M, Mikosch T, Van Drunen H, Lubiniecki AS. 2010. Apparent virus contamination in biopharmaceutical product at centocor. PDA J Pharm Sci Technol 64:471480.[PubMed]
180. Sheu J, Klassen H, Bauer G. 2014. Cellular manufacturing for clinical applications. Dev Ophthalmol 53:178188.
181. U.S. Food and Drug Administration. 2008. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC): Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplant.
182. Griffiths B,. 1991. Products from animal cells, p 207235. In Butler M (ed), Mammalian Cell Biotechnology: A Practical Approach. IRL Press, Oxford, United Kingdom.
183. Butler M,. 1991. The characteristics and growth of cultured cells, p 125. In Butler M (ed), Mammalian Cell Biotechnology: A Practical Approach. IRL Press, Oxford, United Kingdom.
184. Widholm JM. 1972. The use of fluorescein diacetate and phenosafranine for determining viability of cultured plant cells. Stain Technol 47:189194.[PubMed]
185. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:5563.[PubMed]
186. Bulychev A, Trouet A, Tulkens P. 1978. Uptake and intracellular distribution of neutral red in cultured fibroblasts. Exp Cell Res 115:343355.[PubMed]
187. European Parliament and Council of the European Union. 2007. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending. Directive 2001/83/EC and regulation (EC) no 726/2004 (text with EEA relevance). J European Union 324:121137. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF.
188. Stacey GN,. 2007. Risk assessment of cell culture procedures, p 569588. In Stacey GN,, Davis JM (ed), Medicines from Animal Cells. J Wiley & Sons, Chichester, United Kingdom.
189. European Pharmacopoeia. 2014. 5.2.12 Raw materials for the production of cell-based and gene therapy medicinal products (PA/PH/Exp. RCG/T (14) 5 ANP). Pharmeuropa 2014, 26.4 (October 1, 2014).
190. Ministry of Health, Labour and Welfare. 2014. Notification No. 375 Standard for biological ingredients. http://www.pmda.go.jp/operations/shonin/info/saisei-iryou/pdf/H260926-kijun.pdf
191. U.S. Pharmacopeia. 2014. Chapter 1043: Ancillary materials for cell, gene and tissue-engineered products. http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1043.html

Tables

Generic image for table
Table 1.

Citation: Stacey G, Hawkins J. 2017. Cell Lines: Applications and Biosafety, p 299-325. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch14
Generic image for table
Table 2.

Citation: Stacey G, Hawkins J. 2017. Cell Lines: Applications and Biosafety, p 299-325. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch14
Generic image for table
Table 3.

Citation: Stacey G, Hawkins J. 2017. Cell Lines: Applications and Biosafety, p 299-325. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch14
Generic image for table
Table 4.

Citation: Stacey G, Hawkins J. 2017. Cell Lines: Applications and Biosafety, p 299-325. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch14

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error